TINN2 is a European research network (Collaborative Project) supported by the European Commission under the Health Cooperation Work Programme of the 7 th Framework Programme.

News & Events


TINN European Survey on the Use of Antibiotics in NICUs

The survey results are now available and the published article has been published.

Please click here to consult it.


MANY THANKS to all the Neonatal Intensive Care Units that dedicated their time to partipate in the TINN2 survey.


Consortium final meeting on 8th October 2015, in Paris, France

The official event of the TINN2 FP7 European Research Project was organised by Inserm-Transfert on 8th October 2015 in Paris (France).

This meeting gathered together all TINN2 partners for presenting and discussing the latest progresses within TINN2 activities, a project on preclinical studies and paediatric investigation plans for children, under the coordination of the French National Institute of Health and Medical Research (Inserm).

European Congress of Clinical Microbiology and Infectious Diseases, London, United Kingdom 31st to 4th April 2012


TINN2 Project was presented on Poster at the ECCMID congress in London, United Kingdom.

Brochure PDF :

Only for Children Pharmaceuticals

Only for children pharmaceuticals® (O4CP) is a French pharmaceutical company (SAS) founded in 2007 developing adapted medicines for children. The company addresses an important unmet medical need that experts and regulatory authorities have clearly identified: the need for adapted medicines in children.

Because of the heterogeneous needs amongst the paediatric population, O4CP will select a manufacturer capable of specifically addressing this target population’s needs. In case no manufacturer with the desired competences is identified, O4CP will develop the formulation internally.

Coordinator of LOULLA&PHILLA FP7 project, O4CP responded to the call Health 4.2.1 (September 2007) and obtained 15 out of 15.

Vincent Grek, the contact person of O4CP, is a Medical Doctor and is currently founder and president of O4CP. He has 20 years of experience in Research, Medicine and in the Pharmaceutical Industry. Vincent Grek’s areas of expertise include trials in special population (orphan, pædiatric, very severe population), development of biotech products (vaccine, enzyme, gene therapy), trial rescue, GCP (Good Clinical Practices), interaction with regulatory authorities (FDA, EMEA). He has a Doctor of Medicine degree with honors from the University of Liege (Belgium, 1989) and an executive MBA from ESSEC. He is specialized in Internal Medicine with a focus on hemato-oncology, infectious diseases and intensive care (Belgium, 1994).


Back to the list of institutions